clinical trial · NCT05065658
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
Medical University of Graz·—·completed·n = 249
COVID-19 Respiratory InfectionAspergillosisPosaconazole
brief summary
COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients. This study will investigate the efficacy of mold-active prophylaxis with posaconazole for patients with severe SARS (severe acute respiratory syndrome)-CoV-2 infection admitted to the ICU (intensive care unit) in a multi-center case-control study in Europe.
started
Mar 1, 2020
primary completion
Aug 23, 2023
completion
Aug 23, 2023
last updated
Feb 17, 2025
official title
Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol